Jennifer Wellman, MS

Membership Council Chair (2022-2025)


Ms. Wellman is chief operating officer at Akouos and has 20 years of experience in AAV vector gene therapy research and development. In her previous role at Spark Therapeutics, of which she is a co-founder, Ms. Wellman led the regulatory and clinical development for several AAV gene therapies, including Luxturna, the first FDA-approved gene therapy for a genetic disease.

2022

ASGCT Policy Summit

September 26-27, 2022

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.